Abstract
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in gastrointestinal tracts; however, the synchronous or metachronous coexistence of GIST with additional primary malignancy is not common.Here, we present an unusual case of gastric GIST with metachronous primary lung adenocarcinoma diagnosed during his adjuvant treatment with oral receptor tyrosine kinase inhibitor imatinib mesylate (400 mg daily). After 6-month use of imatinib, the patient suffered from dry cough and dyspnea. Subsequent lung biopsy demonstrated adenocarcinoma with diffuse interstitial changes.Our research emphasizes the possibility of an additional primary tumor with GIST, and reminds the clinicians to strengthen the surveillance of the additional cancer during the follow-up of GIST patients.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma of Lung
-
Adenocarcinoma* / complications
-
Adenocarcinoma* / diagnosis
-
Adenocarcinoma* / drug therapy
-
Adenocarcinoma* / physiopathology
-
Antineoplastic Agents / administration & dosage
-
Biopsy
-
Carboplatin / administration & dosage*
-
Gastrointestinal Stromal Tumors* / complications
-
Gastrointestinal Stromal Tumors* / diagnosis
-
Gastrointestinal Stromal Tumors* / drug therapy
-
Gastrointestinal Stromal Tumors* / physiopathology
-
Humans
-
Imatinib Mesylate / administration & dosage*
-
Incidental Findings
-
Lung / diagnostic imaging
-
Lung / pathology
-
Lung Neoplasms* / complications
-
Lung Neoplasms* / diagnosis
-
Lung Neoplasms* / drug therapy
-
Lung Neoplasms* / physiopathology
-
Male
-
Middle Aged
-
Pemetrexed / administration & dosage*
-
Stomach / pathology
-
Stomach Neoplasms* / complications
-
Stomach Neoplasms* / diagnosis
-
Tomography, X-Ray Computed / methods
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Pemetrexed
-
Imatinib Mesylate
-
Carboplatin